{"_id": "64fe80191544b4d920499d0e", "nctID": "NCT04729959", "booleanRepresentation": "{\n    \"$and\": [\n        {\n            \"$and\": [\n                {\n                    \"$or\": [\n                        {\"Histopathologically proven diagnosis of glioblastoma\"},\n                        {\"molecular diagnosis of glioblastoma per Consortium to Inform Molecular and Practical Approaches to Central Nervous System Tumor Taxonomy (c-IMPACT-NOW) criteria\"}\n                    ]\n                },\n                {\n                    \"$or\": [\n                        {\"presence of amplification of EGFR, whole chromosome 7 gain AND whole chromosome 10 loss\"},\n                        {\"TERT promoter mutation\"}\n                    ]\n                }\n            ]\n        },\n        {\"Tumor that is in first recurrence following prior first-line radiation therapy (prior dose >= 40 Gy)\"},\n        {\"Unequivocal radiographic evidence of tumor progression by contrast-enhanced magnetic resonance imaging (MRI) scan within 21 days prior to registration\"},\n        {\n            \"$and\": [\n                {\"focus of progressive, contrast-enhancing tumor that is amenable to FSRT\"},\n                {\"$and\": [\n                    {\"At least 1 cm x 1 cm contrast-enhancing tumor that is no greater than 4 cm in largest dimension\"},\n                    {\"FSRT target is at least 0.5 cm from the optic chiasm and brainstem\"}\n                ]}\n            ]\n        },\n        {\"Surgical cohort only (Phase II only)\": \"Must be a candidate for repeat surgery (significant debulking or gross total resection of the contrast enhancing area) as determined by the neurosurgeon or multidisciplinary team\"},\n        {\"Tumor O-6-methylguanine-deoxyribonucleic acid (DNA) methyltransferase (MGMT) methylation status must be available from any prior GBM tumor specimen; results of routinely used methods for MGMT methylation testing (e.g. mutagenically separated polymerase chain reaction [MSPCR] or quantitative polymerase chain reaction [PCR]) are acceptable)\"},\n        {\n            \"$and\": [\n                {\"Intervals from previous treatments to registration are required to be eligible\"},\n                {\"$and\": [\n                    {\"If prior radiation was < 60 Gy, an interval of at least 12 weeks (84 days) must have elapsed since the completion of radiation therapy\"},\n                    {\"If prior radiation was >= 60 Gy, an interval of least 6 months (182 days) must have elapsed since the completion of radiation therapy, unless the target lesion for FSRT is outside of the 80% isodose line of the original radiation plan\"},\n                    {\"At least 21 days from temozolomide\"},\n                    {\"At least 28 days from any investigational (not Food and Drug Administration [FDA]-approved for glioblastoma) agents, or within a time interval less than at least 5 half-lives of the investigational agent whichever is shorter (Note: anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapeutic antibody or pathway-targeting agents are not allowed)\"}\n                ]}\n            ]\n        },\n        {\"Age >= 18 years\"},\n        {\"Karnofsky performance status >= 70 within 14 days prior to registration\"},\n        {\"History/physical examination within 14 days prior to registration\"},\n        {\"Leukocytes >= 2,500/mm^3 (within 14 days prior to registration)\"},\n        {\"Absolute neutrophil count >= 1,500/mm^3 (within 14 days prior to registration)\"},\n        {\"Absolute lymphocyte count >= 800/mm^3 (within 14 days prior to registration)\"},\n        {\"Platelets >= 100,000/mm^3 (within 14 days prior to registration)\"},\n        {\"Hemoglobin >= 8 g/dL (within 14 days prior to registration)\"},\n        {\"Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled) (within 14 days prior to registration)\"},\n        {\"Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x ULN (within 14 days prior to registration)\"},\n        {\"Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 x ULN (within 14 days prior to registration)\"},\n        {\"Alkaline phosphatase =< 2.5 x ULN (within 14 days prior to registration)\"},\n        {\"Creatinine clearance >= 30 mL/min/1.73 m^2 by Cockcroft-Gault (within 14 days prior to registration)\"},\n        {\n            \"$and\": [\n                {\"Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of receipt of study treatment, and for 60 days (males) or 90 days (females) from the last dose of tocilizumab and for 5 months (150 days) after the last dose of atezolizumab. Administration of atezolizumab or tocilizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\"},\n                {\"Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days prior to registration\"}\n            ]\n        },\n        {\n            \"$and\": [\n                {\"Patients positive for human immunodeficiency virus (HIV) are allowed on study (note: HIV testing is not required)\"},\n                {\"$and\": [\n                    {\"An undetectable viral load within 6 months of registration\"},\n                    {\"A stable regimen of highly active anti-retroviral therapy (HAART)\"},\n                    {\"No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections\"}\n                ]}\n            ]\n        },\n        {\n            \"$and\": [\n                {\"For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\"},\n                {\"$or\": [\n                    {\"Known positive test for hepatitis B virus surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy\"},\n                    {\"Patients who are immune to hepatitis B (anti-Hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B\"}\n                ]}\n            ]\n        },\n        {\n            \"$and\": [\n                {\"For patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\"},\n                {\"$or\": [\n                    {\"Known positive test for hepatitis C virus ribonucleic acid (HCV ribonucleic acid [RNA]) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy\"}\n                ]}\n            ]\n        },\n        {\"The patient or a legally authorized representative must provide study-specific informed consent prior to study entry\"},\n        {\"Availability of prior radiotherapy treatment plan details in Digital Imaging and Communications in Medicine (DICOM) format\"}\n    ],\n    \"$not\": {\n        \"$or\": [\n            {\"Known somatic tumor mutation in IDH1 or IDH2 gene\"},\n            {\"Known germline DNA repair defect (mismatch repair deficiency, POLE mutation, e.g.)\"},\n            {\"Diffuse leptomeningeal disease\"},\n            {\"Known contrast-enhancing tumor in brainstem or spinal cord\"},\n            {\"Patients with clinically significant mass effect or midline shift\"},\n            {\"Prior bevacizumab therapy\"},\n            {\"Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are excluded from this trial. Otherwise, patients with prior or concurrent malignancy are eligible\"},\n            {\"Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation\"},\n            {\"Prior treatment with anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapeutic antibody or pathway-targeting agents\"},\n            {\"Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 4 weeks prior to registration\"},\n            {\"Treatment with systemic immunosuppressive medications (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to registration\"},\n            {\"Systemic corticosteroids used to treat brain edema and/or related symptoms at a dose of > 2 mg of dexamethasone (or equivalent) daily within 5 days prior to registration. Patients receiving systemic corticosteroids for other indications are excluded\"},\n            {\"Patients with increased risk for gastrointestinal perforations including history of diverticulitis\"},\n            {\"Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies\"},\n            {\"History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\"},\n            {\"Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease\"},\n            {\"History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis\"}\n        ]\n    }\n}"}